Theragen Bio has newly appointed Baek Soon-myung, the former Chief Technology Officer (CTO) and head of research, as the CEO, thereby establishing a renewed vision of leading the market through the industrialization of genomic analysis technology. With this appointment, Theragen Bio aims to accelerate innovation in genomic analysis technology by integrating Baek's profound professional knowledge and rich experience, further strengthening its leadership within the industry. This strategic move signifies not merely an executive appointment but also Theragen Bio's strategic initiative to enhance its competitiveness in the global market and redefine the future of genomic technology.

Baek Soon-myung, CEO, is a distinguished medical scientist who graduated from Yonsei University College of Medicine and completed a pathology residency in the United States. He has held positions such as professor at Georgetown University School of Medicine and Director of Pathology at the National Surgical Adjuvant Breast and Bowel Project (NSABP) in the United States, establishing himself as a global authority in the fields of genomic analysis and personalized medicine. The OncotypeDx predictive test for cancer treatment efficacy, developed by Baek in 2004, has aided over 500,000 breast cancer patients in avoiding unnecessary chemotherapy. His research papers have been cited over 80,000 times annually, and he has co-designed and conducted more than 30 clinical protocols, exerting significant influence not only in academia but also in clinical practice.

In South Korea, Baek has served as the inaugural director of the Samsung Cancer Research Institute, director of the Yonsei Center for Life Science, and director of the Breast Cancer Center, dedicating himself to cancer genomic analysis, targeted therapy development research, and mentoring junior researchers. Since assuming the position of head of research at Theragen Bio in September 2020, he has been deeply immersed in the development of personalized cancer vaccines.

The board of directors has stated that such a decision is a strategic one aimed at enhancing Theragen Bio's market leadership in genomic analysis based on its scientific and technological expertise. Baek's pivotal role in significantly strengthening Theragen Bio's competitiveness in clinical sample genomic analysis technology during his tenure as CTO has been highlighted. Now, as CEO, he plans to industrialize the company's research and development achievements and solidify its global competitiveness through strategic management based on scientific technology.

Baek Soon-myung, CEO, stated, "As the CEO of Theragen Bio, I will develop the company into a genomic analysis service provider with a differentiated, self-developed technological foundation." He added, "Based on our unique clinical trial-derived sample analysis technology, we will evolve into a global genomic analysis Contract Research Organization (CRO), strengthen partnerships with global pharmaceutical companies, and prioritize the development of groundbreaking treatments for intractable cancers that currently lack therapies through the development of genomic analysis-based personalized cancer vaccines."